C344 BioVendor


PCSK9 protein (proprotein convertase subtilisin/kexin type 9) plays a major regulatory role in cholesterol homeostasis, mainly by reducing LDL-Receptor levels on the surface of hepatic cells. Reduced LDLR levels result in decreased metabolism of LDL-particles, which could lead to hypercholesterolemia. This activity made PCSK9 a novel target in cholesterol lowering therapy. The PCSK9 inhibitors (PSK9i) are a newer class of injectable drugs that have been shown to dramatically lower LDL cholesterol levels, by up to 60% when combined with a statin. PCSK9 inhibitors are monoclonal antibodies (MAbs), a type of biologic drug. PCSK9 has a key impact not only on circulating LDL-Cholesterol level but also on cardiovascular risk and atherosclerotic process. The determination of PCSK9 levels is obviously of great diagnostic as well as treatment monitoring importance. Applications include atherosclerosis, cardiovascular disease, lipid metabolism and diabetology.
BioVendor’s Human PCSK9 ELISA (RD191473200R) is a sandwich enzyme immunoassay for the quantitative measurement of PCSK9 in human serum and plasma samples (EDTA, citrate, heparin) using a 96-well assay format. The total assay time is less than 3.5 hours. Standard is recombinant protein and components of the kit are provided ready to use, concentrated or lyophilized. Limit of detection is 9 pg/ml.

Supplier: BioVendor Research and Diagnostic Products

Mail the supplier